Summary

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.

Job description

The Opportunity

Partner with PDM leadership and cross-functional stakeholders to support portfolio planning, business operations, and strategic decision-making across the organization.
Lead development analyses, insights, and recommendations that enable effective prioritization, resource allocation, risk management, and execution of business objectives.
Lead portfolio reporting, metrics, dashboards, and other decision-support tools to provide visibility into portfolio performance, organizational capacity, risks, and opportunities.
Lead or contribute to strategic initiatives and operational excellence efforts aimed at improving business processes, organizational effectiveness, and scalability.
Drive cross-functional planning and governance activities by facilitating stakeholder alignment, supporting decision-making forums, and ensuring effective follow-through on key actions and commitments.
Support budgeting and long-range planning activities by driving data analysis, scenario modeling, and business insight generation.
Apply structured problem-solving and analytical approaches to address complex cross-functional challenges and support informed decision-making.
Build strong partnerships across PDM and adjacent functions to promote transparency, alignment, and effective execution of key priorities.
Prepare and deliver clear, concise, and compelling communications, presentations, and recommendations for audiences ranging from working teams to senior leadership.

Required Skills, Experience and Education

B.Sc. in a scientific, engineering, business, or related discipline, with 8+ years of experience within a CMC, Project and Portfolio Management, and/or life sciences management consulting organization.
Robust analytical and problem-solving skills with experience in scenario planning, forecasting, resource modeling, and business analytics; demonstrated ability to translate analytical insights into executive-level communications.
Strong scientific and business acumen with the ability to connect data, portfolio priorities, resource constraints, and organizational objectives into actionable recommendations.
Demonstrated intellectual curiosity and learning agility, with a willingness to quickly develop expertise in new business processes, functional areas, and technical domains.
Ability to influence without authority and build productive working relationships across functions and organizational levels.
Exceptional communication and storytelling skills with the ability to synthesize complex information into clear, concise, and compelling recommendations for senior leadership.
Demonstrated ability to balance strategic thinking with operational execution and deliver results across complex cross-functional initiatives.
Demonstrated success operating in fast-paced, dynamic environments with evolving priorities and ambiguity.
Proven track record of taking ownership, identifying opportunities for improvement, and proactively driving solutions with minimal direction.
Strong project management and facilitation skills with the ability to drive alignment, manage competing priorities, and execute effectively in ambiguous environments.

Preferred Skills

Advanced degree in a scientific, engineering, business, or related discipline.
PMP or similar project management certification.

Requirements

B.Sc. in a scientific, engineering, business, or related discipline
8+ years of experience within a CMC, Project and Portfolio Management, and/or life sciences management consulting organization
Robust analytical and problem-solving skills
Experience in scenario planning, forecasting, resource modeling, and business analytics
Ability to translate analytical insights into executive-level communications
Strong scientific and business acumen
Demonstrated intellectual curiosity and learning agility
Ability to influence without authority and build productive working relationships
Exceptional communication and storytelling skills
Demonstrated ability to balance strategic thinking with operational execution
Demonstrated success operating in fast-paced, dynamic environments
Proven track record of taking ownership and proactively driving solutions
Strong project management and facilitation skills

Benefits

Equity awards
Competitive cash compensation
Learning and development opportunities

Company overview

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.